Filtered By:
Drug: Meridia

This page shows you your search results in order of date.

Order by Relevance | Date

Total 28 results found since Jan 2013.

A transcriptomic atlas of drug-induced endothelial dysfunction in human endothelial cells
Drug-induced vascular burden is a critical challenge in both pharmaceutical development and clinical setting. In the past two decades, multiple drugs have been withdrawn from the market due to unanticipated adverse vascular complications, such as the increased risk of myocardial infarction and stroke (e.g., sibutramine and valdecoxib), heart valvular disease (e.g., pergolide and dexfenfluramine), and haemorrhagic stroke (e.g., phenylpropanolamine). Furthermore, many cancer drugs, such as anthracyclines, tyrosine kinase inhibitors (TKIs), and proteasome inhibitors, are also well-known to elicit a broad spectrum of vascular dysfunctions [1].
Source: Journal of Molecular and Cellular Cardiology - October 27, 2022 Category: Cytology Authors: Chengyi Tu, Yu Liu, Damon R. Williams, Joseph C. Wu Tags: Letter to the Editor Source Type: research

FDA Warns ABX Weight Loss Has Hidden Danger
ABX Weight Loss contains sibutramine, a controlled substance that was removed from the market in October 2010, and could lead to heart attack and stroke
Source: PharmaManufacturing.com - November 16, 2016 Category: Pharmaceuticals Source Type: news

Dream Body 450mg, Dream Body Extreme Gold 800mg, Dream Body Advanced 400mg: Recall - Undeclared Drug Ingredient
Sibutramine may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
Source: FDA MedWatch Safety Alert - July 5, 2016 Category: American Health Source Type: alerts

Step 2 60 Gold by The Body Shot Bar: Recall - Undeclared Drug Ingredients
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
Source: FDA MedWatch Safety Alert - June 7, 2016 Category: American Health Source Type: alerts

Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side‐Effect Profiles
ABSTRACT Pharmacotherapy directed toward reducing body weight may provide benefits for both curbing obesity and lowering the risk of obesity‐associated co‐morbidities. However, many weight loss medications have been withdrawn from the market due to serious adverse effects. Examples include pulmonary hypertension (aminorex), cardiovascular toxicity, e.g. flenfluramine‐induced valvopathy, stroke (phenylpropanolamine), excess non‐fatal cardiovascular events (sibutramine), and neuro‐psychiatric issues (rimonabant ‐ approved in Europe, but not in the US). This negative experience has helped mold the current drug dev...
Source: Diabetes, Obesity and Metabolism - March 1, 2016 Category: Endocrinology Authors: Andrew J. Krentz, Ken Fujioka, Marcus Hompesch Tags: REVIEW ARTICLE Source Type: research

Pediatric obesity: Causes, symptoms, prevention and treatment.
Authors: Xu S, Xue Y Abstract Pediatric or childhood obesity is the most prevalent nutritional disorder among children and adolescents worldwide. Approximately 43 million individuals are obese, 21-24% children and adolescents are overweight, and 16-18% of individuals have abdominal obesity. The prevalence of obesity is highest among specific ethnic groups. Obesity increases the risk of heart diseases in children and adults. Childhood obesity predisposes the individual to insulin resistance and type 2 diabetes, hypertension, hyperlipidemia, liver and kidney diseases and causes reproductive dysfunction in adults. Obe...
Source: Experimental and Therapeutic Medicine - February 4, 2016 Category: Journals (General) Tags: Exp Ther Med Source Type: research

Obesity and Clinical Riskiness Relationship: Therapeutic Management by Dietary Antioxidant Supplementation-a Review.
Abstract Obesity is a global health problem affecting all age groups, leading to many complications such as type 2 diabetes, systemic hypertension, cardiovascular disease, dyslipidemia, atherosclerosis, and stroke. Physiologically, obesity arises from metabolic changes in the tissues and organs of the human body; these changes result in an imbalance between energy intake and energy expenditure, which in turn results in increased fat accumulation in adipose tissue. Such fat accumulation predisposes individuals to development of several health problems. Two different obesity treatment drugs are currently on the mark...
Source: Applied Biochemistry and Biotechnology - April 12, 2015 Category: Biochemistry Authors: Hassan HA, El-Gharib NE Tags: Appl Biochem Biotechnol Source Type: research

Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
Abstract With the recent approval of methylphenidate (MPH) for treating attention-deficit/hyperactivity disorder (ADHD) in adults, the number of patients exposed will increase tremendously. The ongoing debate on the cardiovascular safety of MPH has triggered two large retrospective cohort studies in children and adolescents as well as in young to middle-aged adults. These studies looked into serious cardiovascular events (sudden cardiac death, acute myocardial infarction and stroke) as primary endpoints and concluded that MPH was safe after a mean duration of 2.1 years of follow-up in children and adolescent...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 17, 2015 Category: Neuroscience Source Type: research

Slim-Vie: Public Notification - Undeclared Drug Ingredient
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Source: FDA MedWatch - November 26, 2014 Category: American Health Source Type: news

Bee Thin: Public Notification - Undeclared Drug Ingredient
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Source: FDA MedWatch - November 24, 2014 Category: American Health Source Type: news

Super Extreme Accelerator: Public Notification - Undeclared Drug Ingredient
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Source: FDA MedWatch - November 24, 2014 Category: American Health Source Type: news

Bee Slim: Public Notification - Undeclared Drug Ingredient
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Source: FDA MedWatch - November 24, 2014 Category: American Health Source Type: news

V26 Slimming Coffee: Public Notification - Undeclared Drug Ingredient
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Source: FDA MedWatch - November 5, 2014 Category: American Health Source Type: news

Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
Authors: Antel J, Albayrak O, Heusch G, Banaschewski T, Hebebrand J Abstract With the recent approval of methylphenidate (MPH) for treating attention-deficit/hyperactivity disorder (ADHD) in adults, the number of patients exposed will increase tremendously. The ongoing debate on the cardiovascular safety of MPH has triggered two large retrospective cohort studies in children and adolescents as well as in young to middle-aged adults. These studies looked into serious cardiovascular events (sudden cardiac death, acute myocardial infarction and stroke) as primary endpoints and concluded that MPH was safe after a mean ...
Source: European Archives of Psychiatry and Clinical Neuroscience - August 26, 2014 Category: Psychiatry Tags: Eur Arch Psychiatry Clin Neurosci Source Type: research

Cardiovascular effects of current and future anti-obesity drugs.
Abstract The prevalence of obesity increases and is associated with increases in co-morbidities e.g. type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, several forms of cancer, depression, and may result in reduction of expected remaining lifespan. We have reviewed the adverse effects on the cardiovascular system of anti-obesity drugs now retracted from the market as well as the cardiovascular profile of current drugs and potential pathways which are considered for treatment of obesity. Fenfluramine, and sibutramine were withdrawn due to increased cardiovascular ...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U Tags: Curr Vasc Pharmacol Source Type: research